Recent Treatment Outcome Improvements in Metastatic Soft Tissue Sarcomas

Speaker: Silvia Stacchiotti

Silvia Stacchiotti highlights that with currently available agents we could improve patient's progression-free survival but not overall survival (OS). In 2017 two new agents were approved, olaratumab and eribulin, and they might change the practice pattern regarding the treatment of advanced soft tissue sarcomas (STS). 

In order to provide a valuable tool for the clinician, the sarcoma community is working on a mapping of the activity of all the available drugs against each of the many sarcoma subtypes. Olaratumab is a PDGFR alpha inhibitor approved in front-line for all advanced STS in combination with doxorubicin. This treatment showed an impressive benefit in OS after 18 months compared with doxorubicin only. We are waiting for the final results of the study to know more precisely about the level of improvements.Eribulin has been approved for advanced liposarcoma, all subtypes included. The improvement is in terms of OS which is not common in this field. We are waiting for more results to learn in which subtypes the drug may be more active.


  • Chemotherapy
  • Targeted therapy
  • What's the current benefit for patients
  • Future outlook